15,300 Shares in Teva Pharmaceutical Industries Limited (TEVA) Acquired by Bluestein R H & Co.

Bluestein R H & Co. acquired a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,300 shares of the company’s stock, valued at approximately $269,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. San Francisco Sentry Investment Group CA acquired a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth about $106,000. Bronfman E.L. Rothschild L.P. raised its holdings in shares of Teva Pharmaceutical Industries by 2.6% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after acquiring an additional 94 shares during the last quarter. Penserra Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth about $129,000. Shelter Mutual Insurance Co acquired a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth about $133,000. Finally, Fayez Sarofim & Co. acquired a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth about $204,000. Institutional investors own 52.05% of the company’s stock.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded up $0.01 during mid-day trading on Wednesday, hitting $15.06. 10,220,100 shares of the company were exchanged, compared to its average volume of 15,647,090. The stock has a market cap of $15,290.80, a PE ratio of 3.48 and a beta of 0.55. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries Limited has a 12 month low of $10.85 and a 12 month high of $38.31.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a $0.085 dividend. This represents a $0.34 annualized dividend and a yield of 2.26%. The ex-dividend date of this dividend is Monday, November 27th. Teva Pharmaceutical Industries’s dividend payout ratio is presently -12.10%.

TEVA has been the subject of a number of recent analyst reports. Cantor Fitzgerald set a $10.00 price objective on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Monday, November 27th. Zacks Investment Research raised shares of Teva Pharmaceutical Industries from a “strong sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $21.00 price objective (down from $28.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 31st. BTIG Research raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $24.00 price objective for the company in a research report on Monday, September 11th. Finally, Morgan Stanley set a $15.00 price objective on shares of Teva Pharmaceutical Industries and gave the stock an “underweight” rating in a research report on Thursday, October 5th. Seven equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $21.65.

COPYRIGHT VIOLATION WARNING: This article was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.chaffeybreeze.com/2017/12/06/15300-shares-in-teva-pharmaceutical-industries-limited-teva-acquired-by-bluestein-r-h-co.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply